Burkay Yakar, Aslı Azakoğlu KARACA

Frequency of aspirin use in patients with type 2 diabetes: Is there any effect of concomitant diseases?

Aim: Current guidelines recommend the use of low-dose aspirin in diabetic patients with increased cardiovascular disease risk withno risk of bleeding to prevent cardiovascular events. The aim of this study was to investigate the frequency of aspirin use in Type 2Diabetes Mellitus and the effects of concomitant diseases.Material and Methods: Our retrospective and cross-sectional study was planned of data for rate of aspirin use in Type 2 Diabetesmellitus patients. In our study, the socio - demographic characteristics of the participants, their concomitant diseases with Type2 DM and the drugs they used were questioned. Chi-square test was used for the analysis of categorical variables. P

PDF

___

1. American Diabetes Association. 9. Cardiovascular disease and risk management standards of medical care in diabetes-2018. Diabetes Care 2018;41:86-104.
2. Koskinen SV, Reunanen AR, Martelin TP, et al. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 1998;88:765-70.
3. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529-39.
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. Jama 1979; 241:2035-38.
5. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123:798-813.
6. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intra-venous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS–2. Lancet 1988;2:349-60.
7. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003;26(1):87-8.
8. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26.
9. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321:129-35.
10. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992;268:1292-300.
11. Ogawa H, Nakayama M, Morimoto T, et all. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. JAMA 2008;300:2134-41.
12. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-701.
13. TÜRKDİAB Diyabet Tanı ve Tedavi Rehberi 2018, Diyabet ve Kardiyovasküler hastalıklar. İstanbul: Türkiye Diyabet Vakfı; 2018;75-8.
14. Miller S.R, Littenberg B, Maclean C.D. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovascular Diabetology 2005;4:18.
15. Khalil C.A, Omar O.M, Suwaidi J.A, et al. Aspirin Use and Cardiovascular Outcome in Patients With Type 2 Diabetes Mellitus and Heart Failure: A PopulationBased Cohort Study. J Am Heart Assoc 2018;7:010033.
16. 16. Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med. 2004;164(22):2492-99. (pubmed)
17. 17. Grimes R.T, Bennett K, Tilson L, et al. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients. Br. J. Clin. Pharmacol. 2015;79:1000–1009.(pubmed)
18. Kline J.A, Jonhson J.A, Guirguis L.M, et al. Underuse of Aspirin in Type 2 Diabetes Mellitus: Prevalence and Correlates of Therapy in Rural Canada. Clinical Therapeutics 2004;26:439-46.
19. Onalan E, Gozel N, Yakar B. An evaluation of type 2 diabetes mellitus patients on different oral antidiabetic medications with regard to glycemic control and diabetic complications. Medical Science and Discovery 2019; 6(9):180-5. Doi: 10.17546/msd.